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stop or signifi cantly reduce steroids. With a median follow-up 
of 31 months (3-45) 27 patients are alive and 7 patients died: 
4 due to GVHD progression and 2 for infections; 17 patients 
are in continue response at last follow-up, without additional 
treatments. The RR observed in this second trial, in a larger 
series of patients with steroid-refractory cGVHD seems slightly 
inferior, compared to the RR observed in the fi rst trial, probably 
due to the more stringent response criteria used. Moreover 
the higher median age and the different kind of patients could 
have infl uenced these results: the previous study included only 
patients with skin fi brotic cGVHD and pediatric patients. How-
ever the stable response observed after 12 months and the pro-
mising outcome (Figure 1: OS; Figure 2: EFS), in this very hard 
to treat set of patients, suggest that Imatinib is a valuable option 
in patients with steroid-refractory or steroid-dependent cGVHD.
This work has been supported by AIFA (Agenzia Italiana del 
FArmaco).
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Circulating B-cell activating factor level predicts 
likelihood of chronic GvHD fl are and probability 
of successful steroid taper during extracorporeal 
photopheresis therapy
R. Whittle, H. Denney, A. Alfred, P.C. Taylor
Rotherham General Hospital (Rotherham, UK)
Introduction: Extracorporeal photopheresis (ECP) is an impor-
tant second line therapeutic intervention in steroid refractory 
chronic GVHD (cGVHD) with recognised effi cacy as a steroid 
sparing agent. Few reliable biomarkers predicting ECP response 
exist. B-cell activating factor (BAFF) has described roles 
in immature B-cell survival. Elevated BAFF levels reportedly 
correlate with cGVHD activity and excess BAFF may contribute 
to cGVHD maintenance. We report that BAFF level following 
6 months of ECP therapy predicts the likelihood of disease 
fl are and capacity for successful steroid taper.
Methods: We retrospectively evaluated 28 adult patients under-
going ECP for steroid-refractory, resistant or intolerant cGVHD. 
ECP was performed using the Therakos XTSTM or CellexTM 
devices. ECP treatment schedule was 2-weekly dual treat-
ments for an initial 3 months, then monthly paired treatments 
until at least 12 months. 24/28 patients were receiving steroids 
at start of ECP. Skin disease response was assessed using the 
Modifi ed Rodnan skin scoring system. Extracutaneous organ 
cGVHD response was assessed by reduction in symptoms as 
defi ned by NIH criteria. Disease fl are was defi ned as signifi cant 
symptomatic increase of, or (re)appearance of, GVHD in affec-
ted organ(s). Initiation of steroid or other immunosuppressives 
during treatment was also regarded as loss of disease con-
trol. Successful uninterrupted steroid taper was defi ned as the 
capacity for dose reduction without steroid re-escalation bet-
ween 3 and 18 months of ECP. Soluble BAFF in patient sera 
was measured prior to ECP, and at 3, 6, 9 and 12 months of 
ECP using commercially available enzyme-linked immunosor-
bent assay.
Results: All patients with serum BAFF levels above 4 ng/ml 
following 6 months of ECP therapy (n=15) experienced a 
loss of disease control as evidenced by GVHD fl are between 
3 and 18 months of ECP. This resulted in re-escalation of 
steroid dose in 13/15 patients (87%) and steroid introduction in 
1 patient. Loss of GVHD control was signifi cantly less common 
amongst patients with BAFF levels below 4 ng/ml at 6 months 
of ECP; 6/13 patients experienced disease fl are between 
6 & 18 months (P=0.001, Fishers exact) resulting in steroid 
or cyclosporine re-escalation in 5/13 patients (P=0.002) whilst 
steroid taper without escalation was possible in 7/11 patients 
(P=0.001).
Conclusions: Our data supports further prospective studies to 
assess the potential prognostic value of early BAFF measure-
ment in ECP therapy for cGVHD.
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Rapamycin prevents experimental sclerodermatous 
chronic graft-versus-host disease in mice
L. Belle, M. Binsfeld, S. Dubois, M. Hannon, J. Caers, A. Briquet, 
C. Menten, Y. Beguin, S. Humblet-Baron, F. Baron
University of Liège (Liège, BE)
Background: The most widely used mice model of chronic graft-
versus-host disease (cGvHD) is an MHC-matched bone marrow 
transplantation model of sclerodermatous cGvHD. A limitation 
of that model is that mortality is relatively low, making diffi cult to 
study the impact of potentially therapeutic compounds.
Aims: To develop a more severe model of cGVHD and to assess 
the impact of Rapamycin administration in that model.
Results: Lethally irradiated Balb/C mice were injected with 
10x106 bone marrow cells and 70x106 splenocytes from B10.D2 
donor mice. Twenty-one days later, all mice developed cGvHD. 
For the severe model, donor B10.D2 mice were injected 
with 0.5x106 splenocytes from Balb/C twenty-one days before 
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transplantation. All mice from the severe model (n=8) died a 
median of 32 days while 3 of 7 mice in the classical model survi-
ved beyond day 52. Mean survival was decreased in the severe 
model compared to the classical model (32 days versus 37 
days; p=0.0185). Recipient mice in the severe group experien-
ced higher weight loss, hair loss and skin fi brosis. Numbers of 
T lymphocytes (231.9 ± 151.4 versus 951 ± 532.8; p=0.0032) 
and CD4+ T cells (63.25 ± 41.93 versus 135.0 ± 14.39; 
p=0.0018) per microliter of blood at day 21 were lower in the 
severe group than in the classical model. Moreover, number of 
regulatory T cells (Tregs) was decreased in the severe model 
(1.250 ± 0.8864 versus 8.000 ± 6.753; p=0.0151).
We then investigated whether rapamycin administration could 
prevent GVHD in the severe model. All (n=8) mice treated with 
PBS (placebo) died a median of 32 days after transplantation, 
while 6 of 8 mice given 1 mg/kg/day i.p. rapamycin survived 
beyond day 52 (p=0.0012). Number of Tregs/μl was higher at 
day 21 in rapamycin-treated mice than in mice given PBS 
(2.000±1.195 versus 1.250±0.8864; p=0.0796). Moreover, number 
of naïve CD4+T (10.00±4.192 versus 30.25±5.185; p= 0.0089) and 
effector memory T cells (EMT) (30.67±3.180 versus 67.33±7.881; 
p= 0.0125) were higher in rapamycin mice. Finally, proliferation 
of EMT (assessed by fl ow cytometry using Ki-67) was higher in 
PBS than in rapamycin mice (45.28%±4.084 versus 31.90%±
2.003; p=0.0474).
Conclusion: We have developed a mice model of severe 
cGVHD. Interestingly, rapamycin prevented death from cGVHD 
in that model, perhaps through in vivo expansion of Treg.
Stem Cell Source and Donor
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Different effect of HLA disparity on transplant outcomes 
after single unit cord blood transplantation between 
paediatric and adult patients with leukaemia
Y. Atsuta, M. Takanashi, Y. Morishima, S. Taniguchi, 
S. Takahashi, T. Nagamura-Inoue, K. Kato, Y. Kanda on behalf of 
the HLA Working Group of the Japan Society for Hematopoietic 
Cell Transplantation
Recent advances in unrelated cord blood transplantation 
(UCBT) has provided increased chances for patients with 
hematological malignancies to receive hematopoietic stem cell 
transplantation (HSCT). 
We have investigated the effect of HLA disparity of unrelated 
cord blood on HSCT outcome in children and in adults sepa-
rately. 498 children aged 15 years or younger (HLA -A, -B low 
resolution and -DRB1 high resolution matched, n=82, one 
locus mismatched, n=222, two loci mismatched, n=158, three 
loci mismatched, n=36) (median age, 5 years) and 1,880 adult 
patients (HLA matched, n=71, one locus mismatched, n=309, 
two loci mismatched, n=1,025, three loci mismatched, n=475) 
whose age was 16 years or older (median age, 49 years) at the 
time of transplant were analyzed. Subjects were recipients of 
single unit UCB as fi rst HSCT with leukemia. Median infused 
total nucleated cell number was 5.30 x 107/kg in children and 
2.52 x 107/kg in adults (p<0.001).
With adjusted analyses, in children, HLA two-antigen mismat-
ched UCBT showed signifi cant increased risk of overall mor-
tality (relative risk [RR]=1.61, P=0.042) and transplant-related 
mortality (RR=3.55, P=0.005) compared to HLA matched. Risk 
of relapse did not differ signifi cantly. Risk of mortality increased 
according to the number of mismatched loci (p for trend, 0.043 
and 0.002 for overall mortality and TRM) The risk of relapse 
was not different among HLA disparity groups in children. Risk 
of grade 2 to 4 acute GVHD was increased in one- (RR=2.18, 
P=0.003) and two- (RR=2.51, P=0.001) loci mismatched in 
children. Two-loci mismatched was associated with higher risk 
of grade 3 to 4 acute GVHD in children (RR=2.45, P=0.041). 
In Adults, the risk of mortality did not increase with the num-
ber of mismatched loci (RR=0.98, P=0.924 for one-locus mis-
matched, RR=0.88, P=0.423 for two-loci mismatched, and 
RR=0.95, P=0.746 for three-loci mismatched for overall mor-
tality). In adults, risk of relapse was signifi cantly decreased in 
two- loci mismatched (RR=0.67 P=0.029). Risk of TRM, grade 
2 to 4 or grade 3 to 4 acute GVHD did not differ among HLA 
disparity groups in adults. 
Effect of HLA disparity on transplant outcomes were different 
between children and adults. In children, increased number of 
mismatched HLA loci correlated with increased risk of mortality. 
In adults, there was no increase in mortality with increase in the 
number of mismatched HLA loci.
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Co-infusion of haematopoietic progenitors from a HLA 
non-identical adult donor is a most effi cient strategy 
for cord blood transplants early neutrophil recovery, 
engraftment and survival in adults with haematological 
malignancies
M.N. Fernandez (1), C Regidor (1), G Bautista (1), R Fores (1), 
I.I Sanjuan (1), J.A. Garcia-Marco (1), B. Navarro (1), I. Krsnik 
(1), E. Ojeda (1), S. Gil (1), A. de Laiglesia (1), I. Millan (1), 
M. Kwon (2), J. Gayoso (2), J.L. Diez-Martin (2), R. Duarte (3), 
J:R. Cabrera (1)
(1)Hospital Universitario Puerta de Hierro Majadahonda 
(Majadahonda, ES); (2)Hospital General Universitario Gregorio 
Marañon (Madrid, ES); (3)Hospital Duran i Reynals 
(Hospitalet, ES)
Late engraftment is a risk factor for CBT in adults. To over-
come this limitation in 1999 we developed the “dual transplant” 
method (1): co-infusion of only one CB unit and highly T-deple-
ted  mobilized CD34+ (HP) cells from an adult  third party donor 
(TPD), haploidentical or not. Here we report data from 98 adults 
(61/37 M/F) median weight 70 Kg (42-111) transplanted in 
3 Spanish centers to treat high risk hematological malignancies 
(HM). Indications: Acute Leukemia (AL) 85 (43 AML, 32 ALL), 
other 13.
Transplant products cellularity and HLA compatibility data 
shown in Table 1; 105 CB units were used as a 2nd unit was 
required for 7 patients: 2 rejections; 4 graft failures due to lack 
of viable HP; 1 relapse. 
Conditioning: For 49: 10 Gy fractionated TBI, Fludarabine 60 
mg/m, CTX 120 mg/kg and ATG; other 49 received Busulfan 
3,2 x2-3 mg/kg instead of TBI.
Post-Tx treatment: G-CSF, Prednisone 1 mg/Kg 8-14 days and 
CsA till full CB chimerism. 
Engraftment data shown in Table 1. The TPD did not take 
in 8 cases: 1 due to very early CB engraftment; 6 seemin-
gly due to recipient allosensitation against TPD (mother or 
husband). Other 6 who had engraftment failure/rejection of the 
initial CBT had sustained TPD graft until the take of a second 
CBT, given after 33-94 days preceded by a 2nd condi tioning 
(Fludarabina+ATG± 2 Gy TBI or Thiotepa+Fludarbine+ATG). 
Morbi-mortality and survival data on incidence of TRM, relap-
ses and GVHD are shown in Table 1. In no case were TPD 
cells involved in aGVHD lesions. Most common infections 
were CMV (72 episodes), declining after 3-4 months with 6 
CMV-diseases causing 5 deaths. Other 2 deaths were due to 
toxoplasmosis and 1 each to EBV-PTLS, leishmaniasis and 
scedosporium prolifi cans infection (related to long pre-tx neu-
tropenia).
Conclusions: Time to neutrophil recovery after dual trans-
plants is consistently shorter than reported for other approa-
ches (ex-vivo expansion, double CBT, intrabone infusion), 
resulting in low risk of early infections. This and the favorable 
data on aGVHD and relapses (i.e. GVT) contribute to less 
hospital days, what together with the procedure relative 
low cost translates into favorable costs/results ratio. The 
procedure may allow selection of CBT units prioritizing HLA 
compatibility to cell content and use of a fraction of CBT 
